Canaccord Genuity Initiates Coverage On BridgeBio Pharma with Buy Rating, Announces Price Target of $104

Benzinga Newsdesk www.benzinga.com Positive 75.3%

Neg 0% Neu 0% Pos 75.3%

Canaccord Genuity analyst Whitney Ijem initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Buy rating and announces Price Target of $104.